Biogen Inc. (BIIB) vs Novo Nordisk A/S (NVO)
Biogen Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $129.3B against $33.5B — 3.9× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 40.1×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 0.31%. Novo Nordisk A/S has the higher net margin (35.5% vs 8.32%) and the higher return on invested capital (28.7% vs 3.11%). Across the 22 metrics below, Novo Nordisk A/S leads on 16 and Biogen Inc. on 6.
Valuation
Profitability
| Metric | BIIB | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 73.99% | 80.73% | 72.77% |
| Operating margin | 12.35% | 43.36% | 18.90% |
| Net margin | 8.32% | 35.47% | 8.27% |
| Free cash flow margin | 25.33% | 14.79% | 17.25% |
| Return on equity | 4.58% | 60.84% | 6.97% |
| Return on assets | 2.76% | 22.00% | 2.76% |
| Return on invested capital | 3.11% | 28.67% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack